Express Scripts' TriCare contract renewal removes an overhang, says UBS UBS said Express Scripts successful renewal of the TriCare/Department of Defense PBM contract removes an overhang and should contribute 25c-30c to 2014 earnings. The firm expects shares to react positively and reiterates its Buy rating and $72 price target.
Express Scripts TRICARE contract removes key overhang, says Citigroup Citigroup believes the Express Scripts retaining the Department of Defense's TRICARE Pharmacy Program contract removes a key overhang on the stock and validates the company's business model. Citi reiterates a Buy rating on Express Scripts with a $92 price target.
Attack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.